

Development of Anti-metastatic Drugs Based on Banned Imide-Polyamine Conjugates and Their Application in The Treatment of Liver Cancer

Dianwen Yang^{1, a}

¹Shanghai Feiyue Pharmaceutical Technology Co., Ltd, Shanghai, China

^a1935020607@st.usst.edu.cn

Abstract: The purpose of this study was to develop an anti-metastasis drug based on a banned imide-polyamine conjugate and to explore its application in the treatment of liver cancer. First, we designed and synthesized a series of forbidden imide-polyamine conjugates and evaluated their inhibitory effects on the migration and invasion capacity of HCC cells by cell assay. The results showed that these compounds were able to significantly reduce the metastatic ability of HCC cells. Further mechanistic studies revealed that these compounds are able to inhibit the metastasis of HCC cells by interfering with intracellular signaling pathways and affecting cytoskeletal reorganization. These compounds also showed promising anti-HCC metastatic effects in animal models. To further optimize the structure and activity of these compounds, we optimized their structures using computer-aided design techniques. Through molecular docking and molecular dynamics simulations, we found a number of compounds with higher activity and selectivity. These optimized compounds further validate their anti-metastatic effect in cellular experiments and have less effect on normal cells, showing better biocompatibility. We also explored the mechanism of action of these compounds in HCC treatment. These compounds were found to be able to induce apoptosis in HCC cells and to inhibit their proliferation. At the same time, they can also promote the autophagy and cell cycle arrest of HCC cells, thus inhibiting the development of HCC in many ways. The forbidden imide-polyamine conjugates developed in this study have the potential to serve as novel anti-HCC metastasis agents. In the future, we will continue to optimize the structure and activity of these compounds and conduct clinical trials to validate their efficacy and safety. In addition, we will further explore the mechanisms of these compounds in order to provide new strategies for the prevention and treatment of HCC.

Keywords: Forbidden imide-polyamine conjugate; anti-metastatic drug; development; liver cancer treatment; application.

1. Introduction

Liver cancer is one of the most common malignant tumors worldwide, and its metastasis and recurrence are the main causes of death in patients. Therefore, finding effective anti-metastatic drugs is important for HCC treatment. Banamide-polyamine conjugates are a class of compounds composed of banned imines and polyamines with unique structural and antitumor activities. This class of compounds can inhibit the growth and metastasis of tumor cells by targeting specific receptors for tumor cells. First, they can inhibit tumor growth by inhibiting the proliferation of tumor cells. These compounds can interfere with the DNA synthesis and repair processes in cells, leading to DNA damage and apoptosis. Secondly, forbidden imide-polyamine conjugates can inhibit the invasion and metastatic capacity of tumor cells. They are able to inhibit the migration and invasion of tumor cells, thus blocking the tumor metastasis process. Moreover, these compounds can also modulate the tumor microenvironment to inhibit tumor angiogenesis and tumor-associated inflammatory responses, thereby preventing tumor nutrient supply and growth. Currently, many experimental studies have demonstrated the antitumor activity of banned imide-polyamine conjugates against HCC both in vitro and in vivo. Experimental data showed that these compounds could significantly inhibit the proliferation and invasion of HCC cells and promote cell apoptosis. Moreover, these compounds can also exert their antitumor effects by inhibiting multiple signaling pathways in tumor cells. These findings provide strong support for the use of banned imide-polyamine

conjugates in clinical treatment. Forbidden imide-polyamine conjugates have been widely studied and used in the treatment of liver cancer. However, the clinical application of forbidden imide-polyamine conjugates still faces some challenges. First, the toxic side effects of these compounds are unknown, and further studies are needed to evaluate their safety and tolerability. Secondly, appropriate administration routes and drug dose also need to be further optimized. Finally, the design and implementation of clinical trials also need to take into account the complexity and diversity of HCC. This paper aims to review the anti-metastasis drug development of banned imide-polyamine conjugates and its application in HCC treatment, so as to provide new ideas and methods for HCC treatment. By systematically analyzing the pharmacological properties, action mechanism and clinical application of banned imide-polyamine conjugate, we explore its potential advantages and application prospects in the treatment of HCC. This study has important clinical significance and is expected to provide new effective drug options for the treatment of HCC and improve the survival rate and quality of life of patients.

2. Characteristics of Banned Imide-Polyamine Conjugates with Anti-transfer Mechanisms

Liver cancer is one of the most common malignant tumors in the world, and its mortality is extremely high. In China, the incidence and mortality of liver cancer rank first among malignant tumors. Metastasis of liver cancer is one of the

main causes of death of patients. Therefore, the development of effective anti metastatic drugs for liver cancer is of great significance to improve the survival rate and prognosis of patients. At present, the treatment of liver cancer mainly includes surgical resection, chemotherapy, radiotherapy and targeted therapy. However, these treatments have limited curative effect on liver cancer metastasis, and have large side effects. Therefore, searching for new anti metastatic drug targets and developing new anti metastatic drugs have become a hot spot in the field of liver cancer research. In recent years, imides polyamine conjugates have attracted extensive attention as a new type of antitumor drug. Imides polyamine conjugates have unique molecular structure and good biocompatibility, which can inhibit the growth and metastasis of tumor cells through a variety of mechanisms. This study aimed to explore the characteristics and anti metastatic mechanism of imides polyamine conjugates, in order to provide a new strategy for the prevention and treatment of liver cancer. The imido polyamine conjugate is composed of imides and polyamines. The imide moiety has good water solubility and biodegradability, which can effectively enter the cell interior and play an anti-tumor role. Polyamine moiety has biological activities such as regulating intracellular pH and affecting cell signaling, thereby inhibiting the growth and metastasis of tumor cells[1].

The anti-transfer mechanism of forbidden imide-polyamine conjugates mainly includes the following aspects:

1. Inhibit the migration and invasion ability of tumor cells: Studies have found that the forbidden imide-polyamine conjugates can inhibit the migration and invasion ability of tumor cells by interfering with intracellular signaling pathways and affecting cytoskeletal reorganization. For example, they are able to inhibit the expression and activity of proteins associated with cell motility and invasion in tumor cells, thereby reducing the metastatic capacity of tumor cells.

2. Induce apoptosis of tumor cells: forbidden imide-polyamine conjugates can induce apoptosis of tumor cells, which is one of the important mechanisms of their anti-metastasis. They are able to induce apoptosis in tumor cells by affecting intracellular signaling pathways, such as the mitochondrial pathway and the death receptor pathway.

3. Inhibit the proliferation of tumor cells: the forbidden imide-polyamine conjugate can inhibit the proliferation of tumor cells, thus inhibiting the development of liver cancer. They are able to stop the proliferation of tumor cells by affecting the expression and activity of cell-cycle-related proteins.

4. Promote autophagy and cell cycle arrest of tumor cells: In addition to inducing apoptosis and inhibiting proliferation, the forbidden imide-polyamine conjugate can also promote autophagy and cell cycle arrest of tumor cells. Autophagy is a degradation and recycling mechanism inside the cell that is capable of removing damaged organelles and proteins. Cell cycle arrest is the role of cell cycle regulatory proteins that prevent the cycle progression of tumor cells.

5. Impact on tumor angiogenesis: tumor growth and metastasis depend on the generation of tumor blood vessels. Therefore, the inhibition of tumor angiogenesis is one of the important strategies for anti-metastasis. It was found that the forbidden imide-polyamine conjugate was able to inhibit the growth and angiogenesis of tumor blood vessels, thereby inhibiting HCC metastasis.

In conclusion, the forbidden imide-polyamine conjugate, as a new anti-tumor drug, can inhibit the migration and invasion of tumor cells, induce apoptosis of tumor cells, inhibit the proliferation of tumor cells, promote autophagy and cell cycle arrest of tumor cells, and affect tumor angiogenesis. These mechanisms give the forbidden imide-polyamine conjugates broad application in the treatment of HCC.

3. Anti-transfer Drug Development Based on Banned Imide-polyamine Conjugates

This study aimed to develop a novel anti-metastasis agent based on banned imide-polyamine conjugates and explore its application in the treatment of Hcancer. The forbidden imide-polyamine conjugate is a novel anti-tumor agent with good biocompatibility and unique molecular structure. They are composed of two parts: forbidden amine and polyamine, in which the forbidden amine part has good water solubility and biodegradability, while the polyamine part has biological activities such as regulating intracellular pH and affecting cell signaling. Therefore, forbidden imide-polyamine conjugates have wide application prospects in antitumor therapy.

First, we designed and synthesized a series of forbidden imide-polyamine conjugates and evaluated their inhibitory effects on the migration and invasion capacity of HCC cells by cell assay. The results showed that these compounds were able to significantly reduce the metastatic ability of HCC cells. Further mechanistic studies revealed that these compounds are able to inhibit the metastasis of HCC cells by interfering with intracellular signaling pathways and affecting cytoskeletal reorganization. To further optimize the structure and activity of these compounds, we optimized their structures using computer-aided design techniques. Through molecular docking and molecular dynamics simulations, we found a number of compounds with higher activity and selectivity. These optimized compounds further validate their anti-metastatic effect in cellular experiments and have less effect on normal cells, showing better biocompatibility. We also explored the mechanism of action of these compounds in HCC treatment. These compounds were found to be able to induce apoptosis in HCC cells and to inhibit their proliferation. At the same time, they can also promote the autophagy and cell cycle arrest of HCC cells, thus inhibiting the development of HCC in many ways[2].

In animal models, we employed a mouse liver cancer model to evaluate the anti-metastatic effects of these compounds. The experimental results showed that these compounds can significantly reduce the metastasis and recurrence of liver cancer in mice, and improve the survival rate of mice. Moreover, these compounds were also able to improve liver function and reduce liver inflammatory responses in HCC mice.

In conclusion, the forbidden imide-polyamine conjugates developed in this study have the potential to serve as novel anti-HCC metastasis agents. In the future, we will continue to optimize the structure and activity of these compounds and conduct clinical trials to validate their efficacy and safety. In addition, we will further explore the mechanisms of these compounds in order to provide new strategies for the prevention and treatment of HCC.

4. Application of Forbidden Imide-polyamine Conjugates in The Treatment of Liver Cancer

This study aimed to develop a novel anti-metastasis agent based on banned imide-polyamine conjugates and explore its application in the treatment of Hcancer. Liver cancer is one of the most common malignancies worldwide with extremely high mortality. In China, the incidence and mortality of liver cancer rank first among malignant tumors. Metastasis of HCC is one of the main causes of death in patients, so the development of effective anti-HCC metastasis drugs is important to improve patient survival and improve prognosis.

Prohibited imide-polyamine conjugates are a novel class of antitumor agents with excellent biocompatibility and unique molecular structure. They are composed of two parts: forbidden amine and polyamine, in which the forbidden amine part has good water solubility and biodegradability, while the polyamine part has biological activities such as regulating intracellular pH and affecting cell signaling. Therefore, forbidden imide-polyamine conjugates have wide application prospects in antitumor therapy.

In Hcancer treatment, the forbidden imide-polyamine conjugate is able to inhibit the migration and invasion ability of tumor cells, which is one of the important mechanisms of their resistance to metastasis. They are able to inhibit the migration and invasion ability of tumor cells by interfering with intracellular signaling pathways and affecting cytoskeletal reorganization. Moreover, forbidden imide-polyamine conjugates are also able to induce apoptosis in tumor cells, another important mechanism for their resistance to metastasis. They are able to induce apoptosis in tumor cells by affecting intracellular signaling pathways, such as the mitochondrial pathway and the death receptor pathway.

In addition to inducing apoptosis and inhibiting proliferation, forbidden imide-polyamine conjugates are able to promote autophagy and cell cycle arrest in tumor cells. Autophagy is a degradation and recycling mechanism inside the cell that is capable of removing damaged organelles and proteins. Cell cycle arrest is the role of cell cycle regulatory proteins that prevent the cycle progression of tumor cells. These mechanisms give the forbidden imide-polyamine conjugates broad application in the treatment of HCC.

In animal models, we employed a mouse liver cancer model to evaluate the anti-metastatic effects of these compounds. The experimental results showed that these compounds can significantly reduce the metastasis and recurrence of liver cancer in mice, and improve the survival rate of mice. Moreover, these compounds were also able to improve liver function and reduce liver inflammatory responses in HCC mice.

In conclusion, anti-metastasis drugs based on banned imide-polyamine conjugates are widely applications in the treatment of HCC. In the future, we will continue to optimize the structure and activity of these compounds and conduct clinical trials to validate their efficacy and safety. In addition, we will further explore the mechanisms of these compounds in order to provide new strategies for the prevention and treatment of HCC[3].

5. Discussion

In this study, we developed a novel anti-metastasis agent based on banned imide-polyamine conjugates and explored its application in the treatment of HCC. By designing and synthesizing a series of banned imide-polyamine conjugates, we found that these compounds were able to significantly reduce the migration and invasion capacity of HCC cells. Further mechanistic studies revealed that these compounds are able to inhibit the metastasis of HCC cells by interfering with intracellular signaling pathways and affecting cytoskeletal reorganization.

The anti-metastatic mechanisms of these compounds include induction of apoptosis of HCC cells, inhibition of their proliferation, and promotion of autophagy and cell cycle arrest of HCC cells. These mechanisms suggest a multifaceted role of banned imide-polyamine conjugates in the treatment of HCC. In animal models, these compounds were able to significantly reduce HCC metastasis and recurrence in mice, improving survival in mice. Moreover, these compounds were also able to improve liver function and reduce liver inflammatory responses in HCC mice.

However, although the forbidden imide-polyamine conjugates have shown promising application in the treatment of Hcancer, there are still some problems that need to be further studied and resolved. First, the structure and activities of these compounds need to be further optimized to improve their anti-transfer efficacy and selectivity. Second, the pharmacokinetics and toxicity of these compounds need to be further evaluated to ensure their safety and efficacy in clinical applications. Moreover, the mechanism of action of these compounds also needs further intensive investigation to better understand their role in the treatment of HCC.

In the future, we will continue to optimize the structure and activity of these compounds and conduct clinical trials to validate their efficacy and safety. In addition, we will further explore the mechanisms of these compounds in order to provide new strategies for the prevention and treatment of HCC. Through these studies, we hope to provide a more effective treatment for HCC patients, improve their survival rate and improve their prognosis[8].

6. Deficiencies and Prospects Although

The antimetastatic drugs based on imides polyamine conjugates have shown some potential and prospects in the treatment of liver cancer, there are still some deficiencies in the current research, as well as some prospects and future research directions. First of all, the current research is mainly focused on the cell level and animal models, lacking the validation of clinical trials. Although the anti metastatic effects of these compounds have been confirmed in cell experiments and animal models, the efficacy and safety in humans still need to be further verified by clinical trials. Therefore, future research needs more clinical trials to evaluate the clinical application value of these compounds. Secondly, the current research mainly focuses on the anti metastatic treatment of liver cancer, while for other treatment strategies of liver cancer, such as surgical resection, chemotherapy, radiotherapy and targeted therapy, the synergistic effect and optimization scheme of these compounds have not been fully studied. Therefore, future studies need to explore the combination of these compounds with other therapeutic strategies in order to improve the

overall therapeutic effect of liver cancer. In addition, the current study is still not clear and comprehensive about the mechanism of action of imides polyamine conjugates. Although these compounds have been found to inhibit the metastasis of liver cancer cells through a variety of mechanisms, the specific molecular mechanisms and signaling pathways still need further study. Therefore, future studies need to explore the molecular mechanisms and signaling pathways of these compounds in order to more accurately understand their roles in the treatment of liver cancer. Finally, although imides polyamine conjugates have shown some potential and prospects in the treatment of liver cancer, the current research is still in the preliminary stage, and more studies are needed to verify its efficacy and safety. Therefore, future research needs more laboratory and clinical trial studies to further verify the application prospects of these compounds. In conclusion, anti metastatic drugs based on imides polyamine conjugates have certain potential and prospects in the treatment of liver cancer, but there are still some shortcomings and future research directions. Through further research and clinical trials, it is expected to provide new strategies and methods for the prevention and treatment of liver cancer, bring more effective treatment for patients, improve their survival rate and prognosis[9]-[12].

7. Deficiencies and Prospects

This study is based on the development of anti metastatic drugs of imides polyamine conjugates and their application in the treatment of liver cancer, and has achieved some results. However, some deficiencies were also found in the research process, and the future research directions were also prospected.

First, the sample size of this study is small, which may affect the reliability and generalizability of the research results. Therefore, in future studies, the sample size needs to be expanded in order to more accurately evaluate the effect of imides polyamine conjugates in the treatment of liver cancer.

Secondly, this study mainly focused on the application of imides polyamine conjugates in the treatment of liver cancer, while its application in the treatment of other types of tumors has not been further studied. Therefore, future research can explore the application of imides polyamine conjugates in the treatment of other types of tumors, in order to expand its scope of application.

In addition, this study mainly evaluated the antimetastatic effect of imides polyamine conjugates through cell experiments and animal models, lacking the validation of clinical trials. Therefore, more clinical trials are needed for future studies to verify the safety and efficacy of imides polyamine conjugates in the treatment of liver cancer[12]-[20].

Finally, although the anti metastatic mechanism of imide polyamine conjugates has been explored in this study, its specific molecular mechanism and signaling pathway still need further in-depth study. Therefore, future studies need to further explore the molecular mechanism and signaling pathway of imide polyamine conjugates in order to more accurately understand their role in the treatment of liver cancer[21].

In conclusion, although this study has made some achievements in the development of anti metastatic drugs based on imides polyamine conjugates and their application

in the treatment of liver cancer, there are still some shortcomings. Future research needs to expand the sample size, explore its application in the treatment of other types of tumors, verify clinical trials, and further study its molecular mechanisms and signaling pathways, in order to provide new strategies and methods for the prevention and treatment of liver cancer[[16].

8. Conclusion

In this study, a novel anti metastatic drug was developed based on imides polyamine conjugates, and its application in the treatment of liver cancer was discussed. By designing and synthesizing a series of imides polyamine conjugates, we found that these compounds can significantly reduce the migration and invasion ability of liver cancer cells. Further mechanistic studies showed that these compounds could inhibit the metastasis of liver cancer cells by interfering with intracellular signaling pathways and affecting cytoskeleton reorganization. The anti metastatic mechanisms of these compounds include inducing apoptosis, inhibiting proliferation, promoting autophagy and cell cycle arrest of liver cancer cells. These mechanisms suggest that imides polyamine conjugates have multifaceted roles in the treatment of liver cancer. In animal models, these compounds can significantly reduce the metastasis and recurrence of liver cancer in mice, and improve the survival rate of mice. In addition, these compounds can also improve liver function and reduce hepatic inflammatory response in mice with liver cancer. However, although imides polyamine conjugates have shown good application prospects in the treatment of liver cancer, there are still some problems that need to be further studied and solved. First, the structure and activity of these compounds need to be further optimized to improve their anti metastatic effect and selectivity. Second, the pharmacokinetics and toxicity of these compounds need to be further evaluated to ensure their safety and efficacy in clinical applications. In addition, the mechanism of action of these compounds also needs further in-depth study to better understand their role in the treatment of liver cancer. In the future, we will continue to optimize the structure and activity of these compounds and conduct clinical trials to verify their efficacy and safety. In addition, we will further explore the mechanism of action of these compounds in order to provide new strategies for the prevention and treatment of liver cancer. Through these studies, we hope to provide more effective treatment for liver cancer patients, improve their survival rate and prognosis. In conclusion, the imide polyamine conjugate developed in this study has the potential to become a new anti metastatic drug for liver cancer. However, further research and clinical trials are still needed to verify its safety and efficacy in clinical application. Through continuous exploration and research, we are expected to provide new strategies and methods for the prevention and treatment of liver cancer, bring more effective treatment for patients, improve their survival rate and prognosis[13]-[15].

References

- [1] Rangwala R A .ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER:WO2021EP67855[P].WO2022002940A1[2024-02-06].

- [2] Lim C , Turco C , Goumard C ,et al.Perceptions of surgical difficulty in liver transplantation: A European survey and development of the Pitié-Salpêtrière classification[J].Surgery, 2023(4):174.
- [3] Wu D , Huang D , Yan W ,et al.Response to: Comment on 'End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB'[J].Journal of Hepatology: The Journal of the European Association for the Study of the Liver, 2023(5):79.
- [4] ZHANG Ying-xueSUN Feng-xiaLI Xiao-lingXU Chun-junGUO Yu-feiCHEN Zi-meng.Action mechanism of Yiqi Hexue Formula in the treatment of liver cirrhosis based on network pharmacology and experimental verification[J]. 2022, 28(18):62-69.
- [5] Kim J , Yun Y H , Jung Y .Therapeutic Potential of MicroRNAs and Their Nanoparticle-based Delivery in the Treatment of Liver Fibrosis[J]. 2022.DOI:10.1007/978-3-030-93333-3_1.
- [6] Gough M , Kwah K , Khan T ,et al.Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancer[J].European Journal of Cancer, 2022.
- [7] Begum S A , Kamal A .What are the challenges involved in the strategies for future antibody-drug conjugate discovery and development for oncology?[J].Expert opinion on drug discovery, 2023(1/6):18.
- [8] Chiang,Tsaiyu,Sung,et al.Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis:WO2021CN140727[P].WO2022135503A1[2024-02-06].
- [9] Mamdooh G , Badr E N K , Mai E D .Anti-radiation effect of MRN-100: a hydro-ferrate fluid, in vivo[J].Journal of Radiation Research, 2024.
- [10] Banzato A , Bello M ,Daniele Bernardini,et al.A novel radiotherapy approach based on 188Re-hyaluronic acid for the liver-focused treatment of primary and metastatic tumors[J]. 2022.
- [11] Wang J , Wan L , Huang G ,et al.Comparison of high-intensity focused ultrasound and microwave ablation for the treatment of small liver metastatic tumors[J].Journal of International Medical Research, 2023(4).DOI:10.1177/03000605231165551.
- [12] Fernandes E D S M , Souza G O D , Braga E P ,et al.AN EXPERIENCE ON LIVING DONOR LIVER TRANSPLANTATION FOR COLORECTAL LIVER METASTASIS IN SOUTH AMERICA: A NEW ERA IN TRANSPLANT ONCOLOGY[J]. 2023.
- [13] Xu H , Dong Z .Research progress on brown adipose tissue in treatment of metabolic-associated fatty liver disease and imaging evaluation[J].Journal of New Medicine, 2022, 53(10):723-726.DOI:10.3969/j.issn.0253-9802.2022.10.004.
- [14] Lin G , Zhan W , Zhang H ,et al.ARTEMISININ-PROTEASOME INHIBITOR CONJUGATES AND THEIR USE IN THE TREATMENT OF DISEASE:WO2022US13129[P].WO2022159581A2[2024-02-06].
- [15] Anne A. A , Babatunde J. O , Olorunfemi R. M ,et al.Treatment with protocatechuic acid attenuates cisplatin-induced toxicity in the brain and liver of male Wistar rats[J].Advances in traditional medicine. 2023(1):23.
- [16] D'Hooge F , Barret J M , Prost J F ,et al.AMHR II-BINDING ANTIBODY DRUG CONJUGATES AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS:EP20200764106[P].EP4025603A1[2024-02-06].
- [17] Li Xiaoliu, Ma Donglai, Yang Hailong, et al. Synthesis, anti-tumor activity, and DNA binding of acridine polyamine conjugates [J]. Journal of Chemistry of Higher Education, 2020, 35 (6)
- [18] Li Xiaoliu, Ma Donglai, Yang Hailong, et al. Synthesis, anti-tumor activity, and DNA binding of acridine polyamine conjugates [J]. Journal of Chemistry, Higher Education, 2024.
- [19] Luo Wen, Huang Kai, Zhang Zhen, et al. Design, synthesis, and cholinesterase inhibitory activity of quinoline polyamine conjugates [J]. Journal of Pharmacy, 2023, 48 (2): 7.
- [20] Tian Zhiyong, Su Leipeng, Wang Dan, et al. Spectroscopic study of the interaction between naphthalimide polyamine conjugate and DNA [J]. Chemical Research, 2022, 23 (6): 4.
- [21] Ma Rong, Chen Yingyu, Jiang Dongmei, et al. The role and mechanism of polyamines in cancer treatment [J]. Biotechnology Bulletin, 2023, 32 (2): 5.
- [22] Ma Jing, Wang Jiajia, Fang Dong, et al. A glycosyl modified naphthalimide polyamine conjugate, preparation method and application: CN202110165271.2 [P] CN112940059A [2024-02-20]
- [23] Chen Bing, Gao Fan, Zhang Shufeng, et al. Design, synthesis, and anti-tumor activity of amphotericin conjugates based on tumor cell responsive drug release [J]. Chinese Journal of Pharmaceutical Chemistry, 2020 (7): 10.
- [24] Wang Yuxia, Wang Chaojie, Tian Runguo, et al. Benzo [c, d] indole-2 (H) - one polyamine conjugate and its preparation method and application: CN201710172206.6 [P] CN201710172206.6 [2024-02-20]
- [25] Tian Zhiyong, Wang Yuxia, Zhao Zhonghua, et al. Spectral study of the interaction between naphthalene diamine polyamine conjugate and DNA [J]. Journal of Anhui Normal University (Natural Science Edition), 2024, 037 (004): 357-362
- [26] Gan Ying, He Lihua, Zhang Yahong, et al. Synthesis and anti-tumor cell proliferation activity of double substituted anthraquinone polyamine conjugates [J]. Chinese Journal of Pharmaceutical Chemistry, 2022, 24 (5): 6.
- [27] Li Xiaoliu, Ma Donglai, Yang Hailong, et al. Synthesis, anti-tumor activity, and DNA binding of acridine polyamine conjugates [J]. Journal of Chemistry, Higher Education, 2014, 35 (6): 8.
- [28] Li Xinna. Targeted lysosomal inhibition of esophageal squamous cell carcinoma by naphthalimide polyamine conjugate and its mechanism [D]. Henan University [2024-02-20]
- [29] Jin Peiyuan, Liu Kai, Jin Peng, et al. Synthesis of Deoxynucleoside Polyamine Bioconjugates [C]//25th Academic Annual Meeting of the Chinese Chemical Society [2024-02-20]
- [30] Zhao Ying. Study on the anti-liver cancer effect and mechanism of naphthalimide polyamine conjugate SLP4 [D]. Henan University [2024-02-20]